RxDoctor Payments Data

Michael Gorby, MD

Internal Medicine · Tyler, TXNPI 1366446049

Payments from drug & device makers

$9,236in general payments, 2019–2025

Across 485 payments — averaging $19.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novo Nordisk$896
  • AstraZeneca$865
  • Lilly USA, LLC$855
  • Boehringer Ingelheim$849
  • Pfizer$593
  • plus $4K from 35 others

What the payments were for

  • Food & beverage$9,236100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,236 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$347,684
Medicare patients
360
Services billed
4,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban94$61,552
JardianceEmpagliflozin53$53,507
TrulicityDulaglutide37$48,939
OzempicSemaglutide34$48,456
MounjaroTirzepatide14$19,046
LinzessLinaclotide20$12,797
EntrestoSacubitril/Valsartan13$9,831
MyrbetriqMirabegron14$9,174
FarxigaDapagliflozin Propanediol11$7,946
XareltoRivaroxaban13$6,474
Gabapentin137$3,641
Duloxetine Hcl94$2,937
Lantus SolostarInsulin Glargine,hum.Rec.Anlog45$2,820
Tresiba Flextouch U-100Insulin Degludec16$2,643
Autoshield Duo Pen NeedlePen Needle,dual Safety,diabetc22$2,170

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$855$67,98551 claims
PfizerEliquis$593$61,55294 claims
Boehringer IngelheimJardiance$849$53,50753 claims
Novo NordiskOzempic$896$48,45634 claims
AbbVieLinzess$236$12,79720 claims
NovartisEntresto$218$9,83113 claims
Astellas Pharma US IncMyrbetriq$107$9,17414 claims
AstraZenecaFarxiga$865$7,94611 claims
Johnson & JohnsonXarelto$431$6,47413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →